DANAZOL , BUSULFAN , -, POMALIDOMIDE , FEDRATINIB, RUXOLITINIB, PEGFILGRASTIM , HYDROXYCARBAMIDE , PEGINTERFERON ALFA-2A , -
FEDR-MF-002
Phase 3 small_molecule active
Quick answer
DANAZOL , BUSULFAN , -, POMALIDOMIDE , FEDRATINIB, RUXOLITINIB, PEGFILGRASTIM , HYDROXYCARBAMIDE , PEGINTERFERON ALFA-2A , - for Primary myelofibrosis, post-polycythemia vera myelofibrosis , or post-essential thrombocythemia myelofibrosis is a Phase 3 program (small_molecule) at Celgene Europe Limited with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Celgene Europe Limited
- Indication
- Primary myelofibrosis, post-polycythemia vera myelofibrosis , or post-essential thrombocythemia myelofibrosis
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active